Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis

被引：29

作者：

Shuhaibar, M. ^{[3
]}

McKenna, M. J. ^{[1
,2
]}

Au-Yeong, M. ^{[1
,2
]}

Redmond, J. M. T. ^{[3
]}

机构：

[1] St Michaels Hosp, Dun Laoghaire, Co Dublin, Ireland

[2] St Vincents Univ Hosp, DXA Unit, Dublin 4, Ireland

[3] St James Hosp, Dept Neurol, Dublin 8, Ireland

来源：

IRISH JOURNAL OF MEDICAL SCIENCE | 2009年 / 178卷 / 01期

关键词：

Multiple sclerosis; Immunomodulatory therapy; Bone mineral density; WOMEN;

D O I：

10.1007/s11845-008-0253-9

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Osteoporosis is a complication of multiple sclerosis (MS), especially if corticosteroid therapy is given. Little is known about the effect on bone of immunomodulatory therapy (IMT) for MS. We sought to evaluate bone mass in patients with MS on IMT. We measured bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) in 37 patients with MS who received IMT. Different IMTs were administered: interferon beta-1a in 70%, interferon beta-1b in 27% and Glatiramer in 3%. High-dose pulse corticosteroid therapy (intravenous methylprednisolone 500 mg) was given to 81% ranging from 1 to 17 courses. Both mean BMD Z-score at spine of 0.53 (CI, 0.15-0.92; P = 0.0084) and mean BMD Z-score at femur of 0.72 (CI, 0.42-1.01; P < 0.0001) were significantly greater than zero. IMT may have a favorable effect on bone in patients with MS even in the presence of pulse steroid therapy.

引用

页码：43 / 45

页数：3

共 16 条

[1]

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis -: reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations [J].